Diabetes & Obesity

28th December 2025, A/Prof Chee L Khoo We discussed the Lancet Commission’s clinical obesity 12 months ago. Clinical obesity is obesity in the presence of a clinical disease (whether complication or co-morbidity). This is why the PBS is funding semaglutide for patients with obesity and established cardiovascular (CV) disease and not obesity on its own. […]

11th December 2025, A/Prof Chee L Khoo We all have a handful of patients witth idiopathic intracranial hypertension. It is often diagnosed by someone else incidentally. While the full pathophysiology of the condition is still not clear, we know enough about the condition to know who may be at highest risk and perhaps, diagnose the condition early to prevent visual loss. Medical […]

23rd November 2025, A/Prof Chee L Khoo Patients used to be given tacit recommendations about lifestyle changes for metabolic dysfunction associated fatty liver disease (MAFLD) because it’s “just a little fat in the liver”. For those of us who have that few patients with those liver as well as non-liver complications, we will remember how […]

11th October 2025, A/Prof Chee L Khoo Weekly semaglutide injectable has been around for some years now. Even with my special interest in diabetes and obesity, I am getting confused with all the clinical trials involving semaglutide in patients with obesity with or without diabetes. They all have very innovative acronyms most of them starting […]

22nd August 2025, A/Prof Chee L Khoo We always worry when athlete patients take supplements to improve their workout and performance. We don’t really know what these “supplements” are. We don’t really know whether they work or whether they are safe. One of the most commonly used supplements is creatine. Does it help muscle building […]

13th August 2025, A/Prof Chee L Khoo We know the ongoing cost and availability of anti-obesity medications (AOM) the likes of Wegovy and Mounjaro although we have been assured that the supply issue is behind us now. Part of the problem with cost relate to the manufacturing cost of the devices. In fact, the rate […]

28th July 2025, A/Prof Chee L Khoo We are all aware of the four pillars of treatment in the guideline directed medical treatment (GDMT) of patients with heart failure with reduced ejection fraction (HFrEF) – SGLT2 inhibitors (SGLT2i), angiotensin receptor neprilysin inhibitor (ARNI), beta blockers and mineralocorticoid receptor antagonist (MRA). When we come to heart […]

30th June 2025, A/Prof Chee L Khoo You would have no doubt noticed headlines everywhere about the new criteria for GDM diagnosis that was just released a few days ago. Why is there such a buzz? Why is everyone seemingly that excited? We have covered many of the issues covered by ADIPS over the years […]

30th June 2025, A/Prof Chee L Khoo There are many reasons why some of our patients go vegetarian. A primarily plant-based diet with less meat is supposed to lower the morbidity of chronic diseases, including cardiovascular diseases, type 2 diabetes, and certain cancers [1]. Some patients may choose to reduce their food-related ecological footprint. A […]

27th May 2025, A/Prof Chee L Khoo We know about type 1 to type 3 diabetes mellitus. I didn’t know that there was a type 4 and now they tell us there is a type 5. For someone who has a special interest in things diabetes, this is definitely news to me. Actually, on further […]

27th April 2025, A/Prof Chee L Khoo We recently looked at the LDL-C levels needed to stabilise plaque progression and the LDL-C levels needed to cause plaque regression. Plaque stabilisation and regression leads to reduction in cardiovascular events. Dyslipidaemia (especially LDL-C) is also associated with cognitive impairment and dementia and reducing those numbers with statin […]